IS4328A - Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara - Google Patents

Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara

Info

Publication number
IS4328A
IS4328A IS4328A IS4328A IS4328A IS 4328 A IS4328 A IS 4328A IS 4328 A IS4328 A IS 4328A IS 4328 A IS4328 A IS 4328A IS 4328 A IS4328 A IS 4328A
Authority
IS
Iceland
Prior art keywords
formulation containing
multiple units
proton pump
containing proton
pump blocker
Prior art date
Application number
IS4328A
Other languages
English (en)
Inventor
John Arvid Bergstrand Pontus
Ingmar Lövgren Kurt
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS4328A publication Critical patent/IS4328A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS4328A 1994-07-08 1996-03-04 Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara IS4328A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402431A SE9402431D0 (sv) 1994-07-08 1994-07-08 New tablet formulation
PCT/SE1995/000678 WO1996001624A1 (en) 1994-07-08 1995-06-07 Multiple unit pharmaceutical preparation containing proton pump inhibitor

Publications (1)

Publication Number Publication Date
IS4328A true IS4328A (is) 1996-03-04

Family

ID=20394685

Family Applications (3)

Application Number Title Priority Date Filing Date
IS4326A IS4326A (is) 1994-07-08 1996-03-04 Ný forðakyrni og lyfjablanda sem inniheldur þau
IS4328A IS4328A (is) 1994-07-08 1996-03-04 Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara
IS4329A IS4329A (is) 1994-07-08 1996-03-04 Fjöleiningaskammtar í töfluformi sem innihalda prótónupumpublokkara

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4326A IS4326A (is) 1994-07-08 1996-03-04 Ný forðakyrni og lyfjablanda sem inniheldur þau

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS4329A IS4329A (is) 1994-07-08 1996-03-04 Fjöleiningaskammtar í töfluformi sem innihalda prótónupumpublokkara

Country Status (36)

Country Link
US (1) US5753265A (is)
EP (3) EP0723437B1 (is)
JP (2) JPH09502741A (is)
KR (1) KR100384961B1 (is)
CN (2) CN1134667A (is)
AT (1) ATE275396T1 (is)
AU (1) AU695971B2 (is)
BR (2) BR9506028A (is)
CA (2) CA2170644C (is)
CZ (1) CZ294380B6 (is)
DE (1) DE69533470T2 (is)
DK (1) DK0723437T3 (is)
EE (1) EE03292B1 (is)
ES (1) ES2227556T3 (is)
FI (2) FI961059A (is)
HK (1) HK1008298A1 (is)
HU (2) HU9600572D0 (is)
IL (2) IL114447A (is)
IS (3) IS4326A (is)
MA (1) MA23608A1 (is)
MY (1) MY114388A (is)
NO (2) NO316863B1 (is)
NZ (1) NZ289949A (is)
PL (2) PL313389A1 (is)
PT (1) PT723437E (is)
RU (2) RU2166935C2 (is)
SA (1) SA95160092B1 (is)
SE (1) SE9402431D0 (is)
SI (1) SI0723437T1 (is)
SK (1) SK283841B6 (is)
TN (1) TNSN95076A1 (is)
TR (2) TR199500826A2 (is)
TW (1) TW421599B (is)
UA (1) UA47390C2 (is)
WO (2) WO1996001624A1 (is)
ZA (2) ZA955547B (is)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283626B6 (sk) * 1994-07-08 2003-10-07 Astrazeneca Ab Multijednotková tabletovaná dávková forma, spôsob jej prípravy a jej použitie
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HU227566B1 (en) * 1995-09-21 2011-08-29 Pharma Pass Llc Acid-labile pharmaceutical composition containing omeprazole and process for its preparation
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
AU751066B2 (en) * 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
KR100554924B1 (ko) * 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
DE69924381T2 (de) 1998-07-28 2006-04-20 Takeda Pharmaceutical Co. Ltd. Leicht zerfallende feste zubereitung
PT1105105E (pt) 1998-08-12 2006-07-31 Altana Pharma Ag Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2000026185A2 (en) * 1998-10-30 2000-05-11 The Curators Of The University Of Missouri Omeprazole solution and method of using same
DE69918854T2 (de) 1998-11-18 2005-07-21 Astrazeneca Ab Verbesserter chemischer prozess und eine pharmazeutische zubereitung
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL146504A0 (en) 1999-06-07 2002-07-25 Byk Gulden Lomberg Chem Fab Pharmaceutical compositions containing an acid-labile active compound and processes for the preparation thereof
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2002004411A1 (en) 2000-07-07 2002-01-17 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
EP1341528B1 (en) 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US8765176B2 (en) 2001-06-20 2014-07-01 Takeda Pharmaceutical Campany Limited Method of manufacturing tablet
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
DE60237294D1 (de) * 2001-09-28 2010-09-23 Mcneil Ppc Inc Pharmazeutische zusammensetzung auf fondantbasis
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
DK1459737T3 (da) 2001-10-17 2013-01-02 Takeda Pharmaceutical Granulat indeholdende syreustabilt kemisk middel i stor mængde
JP2006282677A (ja) * 2001-10-17 2006-10-19 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US6902746B2 (en) * 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
FR2845289B1 (fr) * 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004074285A1 (en) * 2003-02-24 2004-09-02 Mitsubishi Pharma Corporation The enantiomer of tenatoprazole and the use thereof in therapy
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005004921A1 (en) * 2003-07-11 2005-01-20 Astrazeneca Ab Solid composition comprising a proton pump inhibitor
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2569961A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc Controlled release pharmaceutical formulation
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
FR2871800B1 (fr) * 2004-06-17 2006-08-25 Sidem Pharma Sa Sa Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
EP1962844A2 (en) * 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
MY151468A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
BRPI0709745A2 (pt) * 2006-04-04 2011-07-26 Cogentus Pharmaceuticals Inc forma de dosagem oral, e, mÉtodo para prevenir ou reduzir a severidade, duraÇço, e/ou sintomas de um distérbio gastrintestinal
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
AU2007276874B2 (en) * 2006-07-28 2010-08-19 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TR200605624A2 (tr) * 2006-10-10 2008-05-21 Nobel İlaç Sanayi̇ Ve Ti̇caret Aş. Farmasötik dozaj şekli
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2044932A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Mechanical protective layer for solid dosage forms
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
KR20100129761A (ko) 2008-03-11 2010-12-09 다케다 야쿠힌 고교 가부시키가이샤 경구 붕해 고형 제제
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
PL2538955T3 (pl) 2010-02-25 2016-04-29 Evonik Roehm Gmbh Formulacja farmaceutyczna lub nutraceutyczna
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
MX2013000827A (es) 2010-07-22 2013-06-28 Lupin Ltd Composicion de tableta de unidad multiple.
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
EP2468263A1 (en) * 2010-12-23 2012-06-27 Laboratorios Del. Dr. Esteve, S.A. Compressed solid dosage forms
CN102805735A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 一种埃索美拉唑肠溶微丸片及其制备方法
RU2647472C2 (ru) * 2011-11-02 2018-03-15 Лабораторьос Дель Др. Эстеве, С.А. Фармацевтическая композиция омепразола
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1545612A (fr) * 1967-06-15 1968-11-15 Dausse Lab Procédé de fabrication de comprimés
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
ES2140391T3 (es) * 1990-06-20 2000-03-01 Astra Ab Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
KR100353384B1 (ko) * 1993-10-12 2002-12-28 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 장용성과립함유정제
SK283626B6 (sk) * 1994-07-08 2003-10-07 Astrazeneca Ab Multijednotková tabletovaná dávková forma, spôsob jej prípravy a jej použitie
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation

Also Published As

Publication number Publication date
NO960949D0 (no) 1996-03-07
CZ73096A3 (en) 1996-07-17
TW421599B (en) 2001-02-11
SE9402431D0 (sv) 1994-07-08
ZA955547B (en) 1996-01-08
CA2170995A1 (en) 1996-01-26
EP0723437A1 (en) 1996-07-31
BR9506028A (pt) 1997-10-14
ZA955546B (en) 1996-01-08
JPH09502740A (ja) 1997-03-18
SA95160092B1 (ar) 2006-06-20
AU2993895A (en) 1996-02-09
EE03292B1 (et) 2000-10-16
EP1452172A2 (en) 2004-09-01
IL114447A (en) 2002-09-12
FI961058A (fi) 1996-03-07
NO960949L (no) 1996-03-07
FI961058A0 (fi) 1996-03-07
WO1996001624A1 (en) 1996-01-25
TR199500826A2 (tr) 1996-06-21
NO316863B1 (no) 2004-06-07
PL313389A1 (en) 1996-06-24
TNSN95076A1 (fr) 1996-02-06
FI961059A0 (fi) 1996-03-07
MY114388A (en) 2002-10-31
IS4326A (is) 1996-03-04
IL114447A0 (en) 1995-11-27
HUT75934A (en) 1997-05-28
SK283841B6 (sk) 2004-03-02
DK0723437T3 (da) 2004-12-13
DE69533470T2 (de) 2005-09-22
NZ289949A (en) 1997-07-27
DE69533470D1 (de) 2004-10-14
CZ294380B6 (cs) 2004-12-15
FI961059A (fi) 1996-03-07
AU695971B2 (en) 1998-08-27
EP1452172A3 (en) 2004-11-03
IL114449A0 (en) 1995-11-27
EP0723437B1 (en) 2004-09-08
CN1134667A (zh) 1996-10-30
RU2538511C2 (ru) 2015-01-10
CN1134668A (zh) 1996-10-30
RU2166935C2 (ru) 2001-05-20
PT723437E (pt) 2004-12-31
ATE275396T1 (de) 2004-09-15
ES2227556T3 (es) 2005-04-01
IS4329A (is) 1996-03-04
EP0724434A1 (en) 1996-08-07
JP3878669B2 (ja) 2007-02-07
NO960948L (no) 1996-03-07
HK1008298A1 (en) 1999-05-07
FI122016B (fi) 2011-07-29
NO960948D0 (no) 1996-03-07
PL180598B1 (pl) 2001-03-30
KR100384961B1 (ko) 2003-08-25
US5753265A (en) 1998-05-19
BR9506029A (pt) 1997-10-14
UA47390C2 (uk) 2002-07-15
HU9600572D0 (en) 1996-05-28
HU9600574D0 (en) 1996-05-28
CA2170644A1 (en) 1996-01-25
WO1996001625A1 (en) 1996-01-25
TR199500825A2 (tr) 1996-06-21
MA23608A1 (fr) 1996-04-01
SK30096A3 (en) 1997-09-10
CA2170644C (en) 2011-02-22
PL313388A1 (en) 1996-06-24
CN1152671C (zh) 2004-06-09
JPH09502741A (ja) 1997-03-18
MX9600856A (es) 1997-10-31
SI0723437T1 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
IS4328A (is) Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara
MX9600857A (es) Forma de dosificacion i en tabletas, con unidades multiples.
CA2214027A1 (en) Multiple unit effervescent dosage forms comprising proton pump inhibitor
SE9500422D0 (sv) New oral pharmaceutical dosage forms
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
SE9902742D0 (sv) New pharmaceutical formultion
JO1881B1 (en) Formula II for multi unit disc calibration
JO1880B1 (en) Format 1 for multi-unit calibration discs
BR0307172A (pt) Composição farmacêutica contendo 2,2-dicloro-12-(4-clorofenil)-ácido dodecanóico
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA